mRNA新冠疫苗接种后心肌炎报告:ACIP 2021年6月更新
2021年6月,ACIP审查mRNA新冠疫苗接种后心肌炎/心包炎报告,病例主要见于年轻男性接种第二剂后。ACIP判定在所有人群中mRNA疫苗获益明确大于风险,EUA已加入心肌炎信息并强调接种前提供事实说明书。
要点
- 心肌炎报告主要见于年轻男性接种mRNA疫苗第二剂后。
- ACIP判定所有人群中mRNA疫苗获益明确大于风险。
- 接种前应提供EUA事实说明书并教育心肌炎症状识别。
核心结论
- ACIP于2021年6月23日判定mRNA新冠疫苗在所有人群(含青少年和年轻成人)中获益明确大于风险。
研究设计与样本
- ACIP会议审查mRNA疫苗接种后心肌炎/心包炎报告病例并讨论获益与风险。
- 背景为FDA对Pfizer-BioNTech(≥16岁)和Moderna(≥18岁)疫苗授予EUA,2021年5月Pfizer-BioNTech EUA扩展至12-15岁。
主要发现
- 心肌炎和心包炎报告主要发生在年轻男性接种第二剂mRNA疫苗后。
- 两种mRNA疫苗均按2剂程序授权,第二剂分别在21天(Pfizer-BioNTech)或28天(Moderna)后接种。
关键数值与推荐
- ACIP推荐所有≥12岁人群接种新冠疫苗。
- EUA已修改加入mRNA疫苗接种后心肌炎信息,接种前应提供EUA事实说明书。
临床怎么用
- 接种前向受种者提供EUA事实说明书。
- 使用CDC患者和提供者教育材料,确保心肌炎症状的及时识别和管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In December 2020, the Food and Drug Administration (FDA) issued Emergency Use Authorizations (EUAs) for the Pfizer-BioNTech COVID-19 (BNT162b2) vaccine and the Moderna COVID-19 (mRNA-1273) vaccine,† and the Advisory Committee on Immunization Practices (ACIP) issued interim recommendations for their use in persons aged ≥16 years and ≥18 years, respectively.§ In May 2021, FDA expanded the EUA for the Pfizer-BioNTech COVID-19 vaccine to include adolescents aged 12-15 years; ACIP recommends that all persons aged ≥12 years receive a COVID-19 vaccine. Both Pfizer-BioNTech and Moderna vaccines are mRNA vaccines encoding the stabilized prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. Both mRNA vaccines were authorized and recommended as a 2-dose schedule, with second doses administered 21 days (Pfizer-BioNTech) or 28 days (Moderna) after the first dose. After reports of myocarditis and pericarditis in mRNA vaccine recipients,¶ which predominantly occurred in young males after the second dose, an ACIP meeting was rapidly convened to review reported cases of myocarditis and pericarditis and discuss the benefits and risks of mRNA COVID-19 vaccination in the United States. Myocarditis is an inflammation of the heart muscle; if it is accompanied by pericarditis, an inflammation of the thin tissue surrounding the heart (the pericardium), it is referred to as myopericarditis. Hereafter, myocarditis is used to refer to myocarditis, pericarditis, or myopericarditis. On June 23, 2021, after reviewing available evidence including that for risks of myocarditis, ACIP determined that the benefits of using mRNA COVID-19 vaccines under the FDA's EUA clearly outweigh the risks in all populations, including adolescents and young adults. The EUA has been modified to include information on myocarditis after receipt of mRNA COVID-19 vaccines. The EUA fact sheets should be provided before vaccination; in addition, CDC has developed patient and provider education materials about the possibility of myocarditis and symptoms of concern, to ensure prompt recognition and management of myocarditis.
引用
- Gargano JW, Wallace M, Hadler SC, et al. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34237049. doi:10.15585/mmwr.mm7027e2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。